It is demonstrated that peripheral blood transcriptomic signatures capture aspects of PD pathophysiology that are not fully explained by nigrostriatal dopaminergic degeneration alone, serving as potential prognostic biomarkers for cognitive impairment and FOG.
Abstract
Parkinson’s disease (PD) is a heterogeneous neurodegenerative disorder with variable long-term outcomes. Blood-based biomarkers for prognostic prediction remain underdeveloped. We aimed to develop a peripheral blood transcriptomic signature for predicting long-term complications in PD using unsupervised data-driven methods. Using RNA sequencing data from 541 PD patients and 180 healthy controls from the Parkinson’s Progression Markers Initiative (PPMI), we employed weighted gene correlation network analysis (WGCNA) to identify disease-associated gene modules. Contrastive principal component analysis was applied to derive a pseudo-temporal (PT) trajectory score reflecting molecular disease progression. The prognostic value of PT scores was assessed through Cox regression for cognitive impairment, freezing of gait (FOG), wearing-off, and levodopa-induced dyskinesia. WGCNA identified two PD-associated co-expression modules enriched for immune/inflammatory pathways. PT scores derived from these modules showed significant correlations with cognitive, autonomic, and axial motor symptoms. In multivariable Cox regression, higher PT scores independently predicted cognitive impairment (HR = 7.31, P = 0.002) and FOG (HR = 3.43, P < 0.001), but not predominantly dopaminergic motor complications. These findings demonstrate that peripheral blood transcriptomic signatures capture aspects of PD pathophysiology that are not fully explained by nigrostriatal dopaminergic degeneration alone, serving as potential prognostic biomarkers for cognitive impairment and FOG.
Parkinsons disease, characterized by the aggregation of alpha-synuclein is a complex neurodegenerative disorder with the fastest global prevalence growth. The identification of shared genes expressed in both blood and brain of Parkinson's disease patients improves the knowledge on peripheral pathophysiology of the dise...
An integrated multi-omics approach provides a robust framework for stage-specific PD monitoring and potential clinical deployment using multi-omics machine learning to identify biofluid-specific signatures and evaluated predictive performance.
A. Galal, Ahmed Moustafa, Mohamed Salama· npj Parkinson's Disease· 0 citations
Cognitive impairment is a common and disabling non-motor manifestation of Parkinson’s disease (PD). Early identification of patients at high risk remains challenging, and the metabolic mechanisms underlying cognitive decline are not fully understood.
We conducted a retrospective cohort study including PD pat...
Zi-Kai Zhou, Jie Liu, Li-Juan Wang et al.· Frontiers in Aging Neuroscie...· 0 citations
NEMPI is interpreted as an abundance-based, neuroimmune-enriched, multibiofluid proteomic composite associated with broad cognitive-motor progression, not as a patient-level prediction tool, clinical threshold, cognition-specific biomarker, or causal mechanism.
Hao Wang, Guo-Qing Wu, Deng-Ke Zhang et al.· Frontiers in Immunology· 0 citations
The AD-specific transcriptomic risk scores (TRSs) developed in this study shows promising clinical utility in AD diagnosis, differential diagnosis, and risk prediction, providing valuable translational medical evidence for early screening and precision prevention of Alzheimer's disease.
Peng-Fei Zhang, Zhongqian Juan, Jia-Lin Han et al.· European Archives of Psychia...· 0 citations
These findings support the use of pathway-specific biomarkers for improving PD diagnostics and monitoring disease progression and support the use of pathway-specific biomarkers for improving PD diagnostics and monitoring disease progression.
Janna van Wetering, M. V. van Ingen, Evelien Timmermans et al.· Movement Disorders· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.